ITCI - Intra-Cellular Therapies, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.94
-0.52 (-4.97%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.46
Open10.17
Bid9.72 x 2900
Ask10.09 x 4000
Day's Range9.57 - 10.24
52 Week Range7.41 - 23.62
Volume1,102,815
Avg. Volume1,254,649
Market Cap548.422M
Beta (3Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)-2.81
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.89
Trade prices are not sourced from all markets
  • Benzinga

    FDA: No Adcom Meeting For Intra-Cellular's Schizophrenia Drug

    Intra-Cellular Therapies Inc (NASDAQ: ITCI) shares were volatile Tuesday after the actively traded, small-cap biotech announced that the FDA has informed the company that it does not plan to hold an Advisory Committee meeting with regard to the review of the company's NDA for lumateperone. Lumateperone is the company's investigational asset that is being evaluated for the treatment of schizophrenia. The company said it has recently submitted to the FDA the results of non-clinical analyses related to toxicology findings in animal studies.

  • GlobeNewswire

    Intra-Cellular Therapies Provides Lumateperone Regulatory Update

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it does not have plans to schedule an Advisory Committee meeting in connection with its review of the Company’s New Drug Application (NDA) for lumateperone for the treatment of schizophrenia. The lumateperone Prescription Drug User Fee Act (PDUFA) goal date is December 27, 2019.

  • How Should Investors React To Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Pay?
    Simply Wall St.

    How Should Investors React To Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Pay?

    Sharon Mates has been the CEO of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) since 2013. First, this article will...

  • 5 Biggest New Drug Approvals Potentially on the Way in 2019
    Motley Fool

    5 Biggest New Drug Approvals Potentially on the Way in 2019

    FDA approvals for these drugs could translate to billions of dollars for a few companies.

  • GlobeNewswire

    Intra-Cellular Therapies Provides Corporate Update and Reports Second Quarter 2019 Financial Results

    NEW YORK, Aug. 07, 2019 -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system.

  • GlobeNewswire

    Intra-Cellular Therapies to Present at the Canaccord Genuity 39th Annual Growth Conference

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Canaccord Genuity 39th  Annual Growth Conference in Boston. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.

  • GlobeNewswire

    Intra-Cellular Therapies to Host Conference Call to Provide Regulatory Update Following Recent Meeting with FDA

    Agreement reached with FDA on submission of additional non-clinical information for NDA review of lumateperone for the treatment of schizophreniaLumateperone PDUFA goal date.

  • Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded
    Zacks

    Biotech Stock Roundup: BIIB Q2 Earnings Top & CELG's Otezla Label Expanded

    Key highlights of the past week include earnings update, collaborations and other pipeline news.

  • GlobeNewswire

    Intra-Cellular Therapies Provides Update on FDA Advisory Committee Meeting for Lumateperone for the Treatment of Schizophrenia

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has cancelled the Psychopharmacologic Drugs Advisory Committee meeting scheduled for July 31, 2019 to discuss the New Drug Application (NDA) for lumateperone for the treatment of schizophrenia. The Company has a meeting scheduled with the FDA shortly and will provide an update following the meeting.

  • Why PulteGroup, Intra-Cellular Therapies, and Clear Channel Outdoor Slumped Today
    Motley Fool

    Why PulteGroup, Intra-Cellular Therapies, and Clear Channel Outdoor Slumped Today

    Bad news in several forms hit some stocks despite a strong session for the overall market.

  • Is Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Potentially Underrated?
    Simply Wall St.

    Is Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Potentially Underrated?

    Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a company with exceptional fundamental characteristics. Upon building...

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For July 9, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Soliton, Inc. (NASDAQ: SOLY ) shares were ...

  • Company News For Jul 9, 2019
    Zacks

    Company News For Jul 9, 2019

    Companies in the news are: AZZ, ITCI, DB and CTST

  • Intra-Cellular Therapies' Candidate Fails in Phase III Study
    Zacks

    Intra-Cellular Therapies' Candidate Fails in Phase III Study

    Intra-Cellular Therapies' (ITCI) lead candidate fails to meet primary endpoint in one of the phase III studies evaluating it in bipolar depression patients. Shares fall.

  • Why Intra-Cellular Therapies Is Tanking Today
    Motley Fool

    Why Intra-Cellular Therapies Is Tanking Today

    Investors disliked the biotech's bad news a lot more than they liked its good news.

  • MarketWatch

    Intra-Cellular Therapies stock down 15% after disappointing Phase 3 trial results

    Shares of biotech Intra-Cellular Therapies fell 15% in premarket trade Monday after the company announced disappointing results from a late-stage trial of its lead drug candidate lumateperone, a potential bipolar depression treatment. The trial, which evaluated 554 patients with bipolar disorder in the U.S., showed that lumateperone was no better than a placebo in helping to relieve symptoms of depression in patients with bipolar disorder. However, Intra-Cellular also announced positive results in a separate global trial of the drug looking at 381 patients with bipolar disorder from around the world. This Phase 3 trial met its primary endpoint; after six weeks of treatment, patients on the drug showed statistically-significant improvement over those on placebo. Intra-Cellular is also conducting a third trial of the drug, looking at it as an adjunctive therapy to lithium or valproate. In early July, Ritu Baral of Cowen said Intra-Cellular would need two positive trials to support filing a new drug application, or NDA. If both the U.S. and global trials looking at lumateperone showed positive results, the company would be able to file an NDA sometime in the second half of 2019, she wrote in a note to clients last week. But if only one of the trials was positive, the company would have to wait for data from the third trial -- evaluating lumateperone as an adjunctive therapy -- to come out. That data won't be available until 2020, she wrote. Shares of Intra-Cellular have gained 18.2% in the year to date through Friday, while the S&P 500 has gained 19.3%.

  • Benzinga

    Intra-Celluar Therapies Falls Following Results For Treatment Of Bipolar Depression

    Intra-Cellular Therapies (NASDAQ: ITCI ) shares resumed trading after the company released mixed study results from two Phase 3 clinical trials evaluating lumateperone as monotherapy in the treatment of ...

  • Reuters

    UPDATE 1-Intra-Cellular drug fails one of two bipolar depression studies; shares fall

    Intra-Cellular Therapies Inc said on Monday its lead drug failed to meet the main goal of one of two late-stage studies in patients with major depressive episodes associated with bipolar disorder. The company's shares fell 6.5% before the opening bell. The treatment, lumateperone, which is being studied as a monotherapy for the condition, failed to show statistically significant improvement in the disease condition compared to placebo in the trial, the company said.

  • MarketWatch

    Intra-Cellular announces positive results in late-stage trials of treatment for bipolar depression

    Intra-Cellular Therapies Inc. on Monday reported positive results from two late-stage trials of a treatment for bipolar depression. The New York-based company said the two phase 3 trials of lumateperone met their primary endpoints. In Study 404, that goal was change from baseline at week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo. Study 404 also met its key secondary endpoint, on the Clinical Global Impression Scale for Bipolar for Severity of Illness, or CGI-BP-S. That study produced positive results for patients with Bipolar type I and Bipolar type 2. "In Study 401, lumateperone did not separate from placebo," the company said in a statement. "A high placebo response was observed in the trial." Study 404 was conducted globally, including in the U.S. and included 381 patients. Study 401 was conducted only in the U.S. and involved 554 patients. "Consistent with previous studies in schizophrenia, lumateperone was well-tolerated in both bipolar depression studies, with a favorable safety profile," said the statement. Shares were halted for the news, but have gained 18.2% in 2019, while the S&P 500 has gained 19.3%.

  • GlobeNewswire

    Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression

    Study 404 met its primary endpoint of change from baseline at Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo (p

  • Benzinga

    The Week Ahead In Biotech: Conferences, Clinical Trial Readouts And Earnings

    Biotech stocks saw muted sentiment in the holiday-shortened week ending July 5 after a strong rebound in the later part of the previous week. Activity was light, although news on clinical trial readouts ...

  • Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in Intra-Cellular Therapies (ITCI) Stock?

    Investors need to pay close attention to Intra-Cellular Therapies (ITCI) stock based on the movements in the options market lately.

  • GlobeNewswire

    Intra-Cellular Therapies Appoints Karen Patruno Sheehy, Esq. as Senior Vice President, Chief Compliance Officer

    Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of Karen Patruno Sheehy, Esq. In prior roles, Karen led compliance functions at Mallincrodt as Senior Vice President, Chief Compliance Officer and at Sanofi as Vice President, Head, North America Compliance.